Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATAI Life Sciences B.V.*

2.41
-0.0700-2.82%
Post-market: 2.430.0200+0.83%19:51 EDT
Volume:4.65M
Turnover:11.47M
Market Cap:483.81M
PE:-2.59
High:2.55
Open:2.55
Low:2.37
Close:2.48
Loading ...

Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025

Insider Monkey
·
02 Mar

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
25 Feb

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

GlobeNewswire
·
20 Feb

ATAI Life Sciences Announces Public Offering Pricing

TIPRANKS
·
14 Feb

ATAI Life Sciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Feb

Atai Life Sciences Prices $55 Million Stock Offering

MT Newswires Live
·
13 Feb

atai Life Sciences Says Pricing Of Registered Underwritten Offering Of 26.1 Million Common Shares At $2.10 Per Share

Reuters
·
13 Feb

Atai Life Sciences Announces Proposed Public Offering Of Common Shares

Reuters
·
13 Feb

atai Life Sciences Announces Proposed Public Offering of Common Shares

GlobeNewswire
·
13 Feb

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

Dow Jones
·
05 Feb

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive
·
03 Feb

Atai Life Sciences And 2 Other Promising Penny Stocks On US Exchanges

Simply Wall St.
·
31 Jan

TD Cowen Reaffirms Their Buy Rating on ATAI Life Sciences (ATAI)

TIPRANKS
·
31 Jan

Atai Life Sciences Reports Positive Topline Results From Alcohol Use Disorder Treatment Study

MT Newswires Live
·
29 Jan

ATAI Life Sciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Jan

ATAI Life Sciences Rated Buy by Patrick Trucchio: Promising Phase 2a Trial Results and Favorable Valuation Analysis

TIPRANKS
·
28 Jan

BUZZ-Atai Life Sciences rises on mid-stage data for alcohol use disorder therapy

Reuters
·
28 Jan

Atai Life Sciences announces results from BPL-003 Phase 2a open-label study

TIPRANKS
·
28 Jan

atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

GlobeNewswire
·
28 Jan

ATAI Life Sciences Board Member Resignation and Changes

TIPRANKS
·
25 Jan